Castle biosciences inc.

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma ...Cutaneous Squamous Cell Carcinoma. Cutaneous squamous cell carcinoma (SCC), non-melanoma skin cancer, is one of the most common cancers with an estimated incidence of more than 1,000,000 cases in the U.S. each year. Approximately 20% of patients have high-risk factors based on tumor depth, histology, anatomic location, and/or immunosuppression.If you're a new customer to Castle Biosciences, please call us when ordering a test. If a returning customer, you can use the requisition form. He received a B.S. degree in molecular biology from Temple University in Philadelphia. Dr. Cook is an author of many medical and scientific publications and a co-inventor of several of Castle Biosciences’ technologies. Bob Cook has served as our Senior Vice President, Research & Development since September 2020, previously serving as our Vice ...Careers. The culture at Castle Biosciences fosters transparency, teamwork and professional growth—all while contributing to our mission to improve health outcomes for patients with dermatologic cancers using innovative technologies and research. The work of our employees directly influences our reputation and a positive experience at Castle ...

This Agreement and Plan of Merger (this “ Agreement”) is made and entered into as of October 18, 2021 (the “ Agreement Date”), by and among Castle Biosciences, Inc., a Delaware corporation (“ Acquirer”), Space Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Acquirer (“ Merger Sub”), Cernostics, Inc., a Delaware …

Castle Biosciences, Inc. believes this leads to better treatment plan decisions, optimized health outcomes and reduced healthcare costs when compared to traditional clinical and pathologic features.Castle Biosciences announced the acquisition Monday after markets closed. Its shares fell 9 percent to $41.60 in early trading Tuesday on the Nasdaq exchange. Business Latest Technology Biotech ...

Cutaneous Squamous Cell Carcinoma. Cutaneous squamous cell carcinoma (SCC), non-melanoma skin cancer, is one of the most common cancers with an estimated incidence of more than 1,000,000 cases in the U.S. each year. Approximately 20% of patients have high-risk factors based on tumor depth, histology, anatomic location, and/or immunosuppression. Nov 2, 2023 · Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September ... 3 Castle Biosciences, Inc, Friendswood, Texas. 4 University of Rochester, Rochester, New York. 5 Icahn School of Medicine at Mount Sinai, New York, New York; Arkansas Dermatology Skin Cancer Center, Little Rock, Arkansas. 6 Oregon Health & Science University, Portland, Oregon.Customer Service: 866-788-9007. CLINICIAN PORTAL. Customer Service: 866-788-9007If you’re planning a trip to Disney World, the Magic Kingdom is a must-see. With its iconic Cinderella Castle, thrilling rides, and classic attractions, it’s no wonder why millions of visitors flock to this beloved park each year.

Castle Biosciences announced the acquisition Monday after markets closed. Its shares fell 9 percent to $41.60 in early trading Tuesday on the Nasdaq exchange. Business Latest Technology Biotech ...

Careers. The culture at Castle Biosciences fosters transparency, teamwork and professional growth—all while contributing to our mission to improve health outcomes for patients with dermatologic cancers using innovative technologies and research. The work of our employees directly influences our reputation and a positive experience at Castle ...

About us. Castle Creek Biosciences, Inc., a late-stage cell and gene therapy company, is using two lentiviral platforms to develop and commercialize therapies for genetic diseases. Website. http ...Nov 2, 2023 · Castle Biosciences Reports Third Quarter 2023 Results. Published: Nov 02, 2023. Q3 2023 revenue increased 66% over Q3 2022 to $61 million. Q3 2023 total test reports increased 52% over Q3 2022. Raising full year 2023 revenue guidance to at least $200 million from at least $180 million. Conference call and webcast today at 4:30 p.m. ET. Castle Biosciences is a pioneer in this field of spatial biology. Our biologically aware AI platform delivered Tissue Cypher® to the clinic, the world’s first precision medicine test to predict the risk of developing esophageal cancer in Barrett’s Esophagus patients – one of the world’s deadliest cancers. Castle Biosciences continues to pursue deployment …DecisionDx-Melanoma is performed in Castle Biosciences’ CAP accredited, CLIA certified laboratory using formalin-fixed, paraffin embedded (FFPE) primary tumor tissue from either a biopsy or excision. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient ...Castle Biosciences is a pioneer in this field of spatial biology. Our biologically aware AI platform delivered Tissue Cypher® to the clinic, the world’s first precision medicine test to predict the risk of developing esophageal cancer in Barrett’s Esophagus patients – one of the world’s deadliest cancers. Castle Biosciences continues to pursue deployment …Castle’s three-year financial targets include anticipated total revenue of $255-$330 million and anticipated net operating cash flow positivity for the year ending December 31, 2025Target Audience and Goal Statement. This activity is intended for dermatologists, surgeons, and other members of the multidisciplinary team. The goal of this activity is that learners will be better able to understand current and emerging treatment strategies being evaluated across the spectrum of melanoma and how these strategies …

Nov 14, 2023 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago. Who can I contact if I have a question? Please call our customer service staff at 866-788-9007 or email [email protected]. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.May 3, 2023 · Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.80 per share a year ago. John C. Cheneval is Executive Director-Business Development at Castle Biosciences, Inc. In his past career he was Vice President-Pharma Partnerships at HTG Molecular Diagnostics, Inc. and Executive...Cutaneous Squamous Cell Carcinoma. Cutaneous squamous cell carcinoma (SCC), non-melanoma skin cancer, is one of the most common cancers with an estimated incidence of more than 1,000,000 cases in the U.S. each year. Approximately 20% of patients have high-risk factors based on tumor depth, histology, anatomic location, and/or immunosuppression.

Leveraging artificial intelligence-based technology, DiffDx-Melanoma provides a high level of accuracy and low technical failure. Validation of the test included a variety of benign and malignant lesions. In the clinical validation study, DiffDx-Melanoma provided a clinically actionable result in greater than 96% of reported cases.

Nov 2, 2022 · Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.47 per share a year ago. Belgium, a country known for its rich history, stunning architecture, and vibrant culture, offers a plethora of attractions for visitors to explore. From medieval castles to modern art galleries, Belgium has something for everyone.Castle Biosciences, Inc. (NASDAQ: CSTL) Castle is a commercial-stage diagnostics company, focused on providing diagnostic and prognostic testing services for dermatological cancers and mental ...Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.Deciding the frequency and intensity of follow-up and surveillance. DecisionDx-SCC is performed on formalin-fixed, paraffin embedded (FFPE) primary tumor tissue from either a biopsy or excision. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.May 3, 2023 · Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.80 per share a year ago. Nov 30, 2023 · Castle Biosciences, Inc. (CSTL) Q3 2023 Earnings Call Transcript SA Transcripts Fri, Nov. 03 Castle Biosciences GAAP EPS of -$0.26 beats by $0.50, revenue of $61.5M beats by $12.94M Castle Biosciences works with all insurance providers, including Medicare, Medicaid, commercial insurers, and the VA to secure coverage and payment for the DecisionDx-Melanoma test. Castle will submit insurance claims and manage the insurance billing process on behalf of patients. The company also sponsors an industry-leading Patient …Founder, President and CEO. Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President, Chief Executive Officer and as a member of our board of directors since inception. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation (now Merck), Integrated ...MyPath Melanoma has over 35,000 clinically resulted cases and 9 publications including validation to outcomes. DiffDx-Melanoma offers a neural network, artificial intelligence-designed algorithm with a low rate of intermediate results. The test was validated in cutaneous melanocytic lesions to accurately differentiate between benign and ...

Castle Biosciences has not completed the preparation of its financial statements for the fourth quarter or full-year-ended Dec. 31, 2022.The preliminary, unaudited information presented in this press release for the quarter and year-ended Dec. 31, 2022, is based on management’s initial review of the information presented and its current expectations, …

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.80 per share a year ago.

Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Castle Biosciences, Inc. Stock Symbol NASDAQ:CSTL. Company Type For Profit. Contact Email [email protected]. Phone Number 602-535-1997. Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer.Jul 24, 2023 · Castle Biosciences Inc’s price is currently up 15.45% so far this month. During the month of July, Castle Biosciences Inc’s stock price has reached a high of $20.96 and a low of $13.18. Over the last year, Castle Biosciences Inc has hit prices as high as $36.10 and as low as $9.26. Castle Biosciences works with all insurance providers, including Medicare, Medicaid, commercial insurers, and the VA to secure coverage and payment for the DecisionDx-Melanoma test. Castle will submit insurance claims and manage the insurance billing process on behalf of patients. The company also sponsors an industry-leading Patient …View a summary page of this 2023 CONTRACT to CASTLE BIOSCIENCES, INC. from the Department of Veterans Affairs.Castle Biosciences, Inc. believes this leads to better treatment plan decisions, optimized health outcomes and reduced healthcare costs when compared to traditional clinical and pathologic features.Castle Biosciences Inc (CSTL) USD0.001 ; Trade low · $19.59 ; Year low · $9.26 ; Previous · $0.13 ; Volume · n/a ; Dividend yield · 0.00%.FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Centers for ...Principal Scientist at Castle Creek Biosciences | Expert in Cell and Gene Therapy Philadelphia, PA. Connect Parin Mehta Process Development Supervisor at Castle Creek Biosciences, Inc. ...A Focus on Transforming Disease Management. Our approach to product development starts by identifying areas of unmet medical need where precision medicine could significantly improve disease staging and/or patient care decisions. We focus first on confirming the clinical challenges of these unmet needs and look for opportunities where current ...MyPath Melanoma has over 35,000 clinically resulted cases and 9 publications including validation to outcomes. DiffDx-Melanoma offers a neural network, artificial intelligence-designed algorithm with a low rate of intermediate results. The test was validated in cutaneous melanocytic lesions to accurately differentiate between benign and ...Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.

Castle Biosciences works with all insurance providers, including Medicare, Medicaid, commercial insurers, and the VA to secure coverage and payment for the DecisionDx-Melanoma test. Castle will submit insurance claims and manage the insurance billing process on behalf of patients. The company also sponsors an industry-leading Patient …Who can I contact if I have a question? Please call our customer service staff at 866-788-9007 or email [email protected]. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.29 Jun 2023 ... 1Castle Biosciences, Inc, Friendswood, TX 2Surveillance Research Program, Division of Cancer Control & Population Sciences, National Cancer ...Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.47 per share a year ago.Instagram:https://instagram. ge gas turbineapple shortyieldmax dividendecopetrol sa stock Castle Biosciences, Inc. (NASDAQ:CSTL) posted its Q2 results on August 8, reporting a GAAP loss per share of $0.06, beating expectations by $0.70. Its revenue of $34.8 million climbed 52.9% year ...Castle Biosciences, Incorporated is a molecular diagnostics company that develops diagnostic and prognostic assays for rare cancers. Castle's mission is to serve individuals afflicted with rare cancers by offering accurate prognostic tests which provide information for making critical decisions regarding an individual's surveillance and ... hexclad in indiawho are the best financial advisors Nov 2, 2022 · Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.47 per share a year ago. vangaurd 2040 Tracfone Wireless Inc has been a leading player in the telecommunications industry, offering innovative solutions and cutting-edge technology to its customers. With a focus on providing reliable and affordable wireless services, Tracfone ha...C/O CASTLE BIOSCIENCES, INC. 505 S. FRIENDSWOOD DRIVE, SUITE 401 (Street) FRIENDSWOOD: TX: 77546 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol CASTLE BIOSCIENCES INC [ CSTL] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X: Director: